Pacific Edge reviews US pricing for new Cxbladder test, trading halted

Pacific Edge says Cxbladder Triage Plus delivers “significant performance improvements” compared to its existing tests. (Image: Pacific Edge)

Rebecca Howard

Tue, 29 Apr 2025

Pacific Edge has been placed on a trade halt while it reviews draft gapfill or reimbursement rates for its new Cxbladder Triage Plus test from the US Centres for Medicare and Medicaid Services.“[It said it's] reviewing the prices and the associated documentation and needs time to assess the implications of them, consult with its advisers and industry partners, and prepare an announcement that provides context to investors.”Gapfill prices are proposed reimbursement rates for new or unpriced clinical diagnostic laboratory tests.Th...

Subscribe to BusinessDesk

Stay informed on business, government and financial developments across New Zealand.

Deeply researched, twice-edited and fact-checked news
Annual subscribers also receive a complimentary subscription to The Wall Street Journal
Personalised email news alerts, plus gift up to 5 stories a month to non-subscribers

You can cancel anytime with two clicks, an email or a phone call.
Find out more.

We are serious about journalism.

Already a Subscriber ? Sign in here.

Name {{ registerForm.errors.get('name') }}

Email address {{ registerForm.errors.get('email') }}

Phone Number {{ registerForm.errors.get('phone') }}

Job Title {{ registerForm.errors.get('title') }}

Password Minimum password length of 8 characters.
Require at least one upper and lowercase, numeric, and special character. {{ registerForm.errors.get('password') }}

Repeat password {{ registerForm.errors.get('password_confirmation') }}

We had trouble validating your card. It's possible your card provider is preventing us from charging the card. Please contact your card provider or customer support.

Credit Card

Cardholder's name

{{ __(plans[index].name) | capitalize }} {{ plans[index].attributes.old_price | currency }} {{ plans[index].price | currency }}

All subscriptions auto renew but are easy to cancel.

I Accept The Terms Of Service

{{ registerForm.errors.get('terms') }}

Tax: {{ taxAmount(selectedPlan) | currency }}

Total Price Including Tax: {{ priceWithTax(selectedPlan) | currency }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerSeat ? '/ '+ spark.seatName : '' }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerTeam ? '/ '+ __('teams.team') : '' }} / {{ __(selectedPlan.interval) | capitalize }}

Markets Market Close

NZ stocks take Wall Street lead to end down 1%

The S&P/NZX 50 Index closed down 133.41 points or 0.98% at 13,464.46.

Jamie Gray 14 Nov 2025

Primary Sector

Comvita deal fails, attention turns to capital raise

“It is your company, and ultimately, shareholders determine its future.”

Riley Kennedy 14 Nov 2025

Comvita deal fails, attention turns to capital raise

Primary Sector

Synlait Milk increases working capital facility

Its annual meeting is next week.

Riley Kennedy 14 Nov 2025

Synlait Milk increases working capital facility

Sponsored

Cybersecurity skills gap leaving Kiwi businesses at risk - report

A cybersecurity skills shortage is creating additional cyber risks, according to a new global report.

Fortinet

Sponsored

Spark’s partner strategy sets the bar for innovation

Spark

More Markets

Markets Market Close

NZ stocks take Wall Street lead to end down 1%

The S&P/NZX 50 Index closed down 133.41 points or 0.98% at 13,464.46.

Jamie Gray 14 Nov 2025

Markets

Zoono says it knows no reason for share price surge, halt lifted

A trading halt granted by the ASX to Australian-listed New Zealand antimicrobials manufacturer Zoono on Wednesday after a price query has been lifted after the company said it knew of no reason for its share price soaring.Its share price rose from 0.09c to 0.18c on volumes much h...

Denise McNabb 14 Nov 2025